Read More 2 minute read Analyst Color Analyst Ratings News Price Target Reiteration Tech Nutanix’s Internal Investigation Limits Outlook, Still Analysts Expect Minimal Impact, Remain Optimistic On Moderate Deal Elongation By Anusuya Lahiri March 7, 1:07 PM Needham analyst Mike Cikos reiterates Nutanix Inc (NASDAQ: NTNX) NTNX
Read More 1 minute read Analyst Ratings News Price Target Reiteration EF Hutton Reiterates Buy on Small Pharma, Maintains C$5 Price Target By Benzinga Newsdesk March 7, 12:27 PM EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target. TSXV:DMT
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target By Benzinga Newsdesk March 7, 12:24 PM HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target. NVCT
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $11 Price Target By Benzinga Newsdesk March 7, 12:23 PM HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $11 price target. OCUL
Read More 1 minute read Analyst Ratings News Price Target Reiteration Cantor Fitzgerald Reiterates Overweight on Allakos, Maintains $7 Price Target By Benzinga Newsdesk March 7, 9:49 AM Cantor Fitzgerald analyst Jennifer Kim reiterates Allakos (NASDAQ:ALLK) with a Overweight and maintains $7 price target. ALLK
Read More 1 minute read Analyst Ratings News Price Target Reiteration Benchmark Reiterates Buy on Quanex Building Prods, Maintains $31 Price Target By Benzinga Newsdesk March 7, 9:35 AM Benchmark analyst Reuben Garner reiterates Quanex Building Prods (NYSE:NX) with a Buy and maintains $31 price target. NX
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Sector Perform on MFA Finl, Maintains $11 Price Target By Benzinga Newsdesk March 7, 9:04 AM RBC Capital analyst Kenneth Lee reiterates MFA Finl (NYSE:MFA) with a Sector Perform and maintains $11 price target. MFA
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Outperform on Chimera Investment, Maintains $7 Price Target By Benzinga Newsdesk March 7, 9:01 AM RBC Capital analyst Kenneth Lee reiterates Chimera Investment (NYSE:CIM) with a Outperform and maintains $7 price target. CIM
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Outperform on American Water Works, Maintains $180 Price Target By Benzinga Newsdesk March 7, 8:57 AM RBC Capital analyst Shelby Tucker reiterates American Water Works (NYSE:AWK) with a Outperform and maintains $180 price target. AWK
Read More 1 minute read Analyst Ratings News Price Target Reiteration Credit Suisse Reiterates Outperform on Inhibrx, Maintains $46 Price Target By Benzinga Newsdesk March 7, 8:39 AM Credit Suisse analyst Judah Frommer reiterates Inhibrx (NASDAQ:INBX) with a Outperform and maintains $46 price target. INBX